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Abstract
 
Previously, we have shown that systemically administered
radiolabeled interleukin 1
 
a
 
 (IL-1
 
a
 
) accumulates preferen-
tially in inflammatory foci in mice. Since inflammation is
characterized by influx of leukocytes, which represent IL-1
receptor (IL-1R) positive cells, radiolabeled IL-1 may spe-
cifically localize in inflammation by binding to its receptors
on infiltrated leukocytes. This hypothesis was tested in a se-
ries of studies in mice with acute focal inflammations. Evi-
dence for specific IL-1–IL-1R interaction in induced inflam-
mation was found: microscopic autoradiography revealed
 
that 
 
125
 
I-IL-1
 
a
 
 localized at the site of inflammatory cells
with time; 
 
125
 
I-myoglobin, a similar-sized protein with no
known interactions in vivo, was not retained in the inflam-
mation. Furthermore, the uptake 
 
125
 
I-IL-1
 
a
 
 in inflamma-
tory tissue was significantly lower in neutropenic mice than
in immunocompetent mice (0.05
 
6
 
0.004 vs. 0.65
 
6
 
0.06% ID/g
at 48 h after injection,
 
 P 
 
, 
 
0.0007). Moreover, the uptake of
 
125
 
I-IL-1
 
a
 
 at the inflammatory site could be blocked with
the anti–IL-1R type II antibody 4E2. At 48 h after injection,
the uptake with and without blocking the type II IL-1R was
0.13
 
6
 
0.01 and 0.65
 
6
 
0.05% ID/g, respectively (
 
P
 
 , 
 
0.0001).
These in vivo studies provide evidence that systemically ad-
ministered radiolabeled IL-1
 
a
 
 localizes in inflammatory tis-
sue by specific receptor binding, predominantly by binding
to the type II IL-1R. (
 
J. Clin. Invest.
 
 1997. 100:2970–2976.)
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Introduction
 
IL-1 is a 17-kD protein, produced by monocytes as a response
to endotoxin. Two forms of IL-1, IL-1
 
a
 
 and IL-1
 
b
 
, have been
discovered, binding to two types of receptors on a wide variety
of cells. The type I IL-1 receptor (IL-1R), a 80-kD glycopro-
tein, is found on T cells, fibroblasts, hepatocytes, and endothe-
lial cells, whereas B cells, macrophages, monocytes, and neu-
trophils express the 68-kD type II IL-1R (1). IL-1 binds to
both receptors with affinity in the picomolar range (2).
Since infection and inflammation are characterized by in-
flux of predominantly IL-1R positive leukocytes, systemically
administered IL-1 may preferentially localize in inflammatory
tissue by means of specific receptor binding. Recently, local-
ization of radiolabeled IL-1
 
a
 
 in 
 
Staphylococcus aureus
 
–induced
infections in mice was demonstrated (3). It cleared rapidly
from noninflamed tissues.
Receptor binding of IL-1 to murine leukocytes has been
well characterized both in vitro and ex vivo (2, 4, 5). However,
in vivo in mice, receptor binding has not been demonstrated
directly but only indirectly via inhibition of IL-1–induced bio-
logic activity by blockade of type I IL-1Rs (6–10). In vivo bind-
ing to type II IL-1Rs could not be shown due to lack of effect
of type II IL-1R blockade on biologic activity (10). The
present paper describes a series of studies conducted to vali-
date the hypothesis of specific receptor binding of IL-1
 
a
 
 in
inflammation in mice. Binding of systemically administered
IL-1
 
a
 
 to type I as well as type II IL-1Rs was investigated by
antibody-blocking studies. Our studies demonstrate localiza-
tion of IL-1
 
a
 
 in inflammatory tissue by specific binding to type II
IL-1Rs on locally present infiltrated leukocytes.
 
Methods
 
Mice.
 
Female Swiss mice weighing 20–25 g (Harlan Netherlands B.V.,
Zeist, The Netherlands) were kept in cages (5–15 mice per cage) and
fed standard laboratory chow and water ad libitum.
 
Reagents.
 
Human recombinant IL-1
 
a
 
 (specific activity of 3
 
 3 
 
10
 
8
 
U/mg) was kindly provided by Dr. P. Lomedico (Hoffman-La Roche,
Nutley, NJ). Myoglobin was purchased from Sigma Chemical Co. (St.
Louis, MO). The anti–IL-1R type I antibody (35F5) and the anti–IL-1R
type II antibody (4E2) (both monoclonal rat IgG) were prepared at
Hoffmann-LaRoche.
 
Radioiodination.
 
IL-1
 
a
 
 and IL-1
 
b
 
 were radiolabeled using the io-
dogen method (11). In brief, for microscopic autoradiography studies,
10 
 
m
 
g IL-1
 
a
 
 (0.68 mg/ml) in 10 
 
m
 
l 0.5 M and 80 
 
m
 
l 50 mM phosphate
buffer, pH 7.2, and 111 MBq Na
 
125
 
I (Amersham International, Amer-
sham, UK; specific activity of 570 GBq/mg) were added to glass
tubes, precoated with 25 
 
m
 
g of 1,3,4,6-tetrachloro-3
 
a
 
,6
 
a
 
-diphenylglu-
couril (Pierce, Rockford, IL). For all other studies, 3 
 
m
 
g IL-1
 
a
 
 (0.68
mg/ml) or 3 
 
m
 
g IL-1
 
b
 
 (1 mg/ml) was labeled with 15–20 MBq Na
 
125
 
I.
The reaction was allowed to proceed for 10 min at room temperature,
after which the reaction mixture was eluted with 0.5% BSA in PBS
on a Sephadex column (PD-10; Pharmacia, Uppsala, Sweden) to sep-
arate labeled IL-1
 
a
 
 and IL-1
 
b
 
 from free 
 
125
 
I. The void fractions were
pooled and sterilized through a 0.2-
 
m
 
m filter.
Analogously, 10 
 
m
 
g myoglobin (1 mg/ml), a protein with a molec-
ular mass (18 kD) similar to IL-1
 
a
 
 and IL-1
 
b
 
 without any known in-
teractions in vivo, was labeled with Na
 
125
 
I.
The labeling efficiency of IL-1
 
a
 
, IL-1
 
b
 
, and myoglobin was be-
tween 50 and 80%. For the microscopic autoradiography studies,
 
Address correspondence to Conny J. van der Laken, M.D., Depart-
ment of Nuclear Medicine, University Hospital Nijmegen, P.O. Box
9101, 6500 HB Nijmegen, The Netherlands. Phone: 31-24-3613813;
FAX: 31-24-3618942; E-mail: J.vanderLaken@Nugen.AZN.NL
 
Received for publication 20 June 1997 and accepted in revised
form 9 October 1997.
 
 Systemically Administered IL-1
 
a
 
 Localizes in Inflammation
 
2971
 
both IL-1
 
a
 
 and myoglobin were labeled with Na
 
125
 
I at a specific activ-
ity of 8–12 MBq/
 
m
 
g. The specific activity used in all other studies was
3–4 MBq/
 
m
 
g.
The radiochemical purity of the radiolabeled proteins was deter-
mined by instant thin-layer chromatography (ITLC) on Gelman
ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M
citrate, pH 5.0, as the solvent. The radiochemical purity of all radiola-
beled proteins was 
 
.
 
 96% after removal of unbound iodine.
Typically, the receptor binding fraction and the dissociation con-
stant of radioiodinated IL-1 preparations were 70–95% and 5 
 
3
 
 10
 
2
 
11
 
mol/liter, respectively, as determined on the murine cell line EL-4-6.1,
a variant subline of EL-4 thymoma cells (12), a kind gift of Dr. H.R.
MacDonald (Ludwig Institute for Cancer Research, Epalinges, Swit-
zerland) (3).
 
Mouse model of inflammation.
 
Focal inflammations in the left
calf muscles of ether anesthetized mice were induced either with 2
 
 3
 
10
 
7
 
 colony forming units of 
 
S. aureus
 
 in 0.05 ml 50–50% suspension of
autologous blood and normal saline or with 0.05 ml 7.5% zymosan in
sterile saline. In some experiments, before the induction of focal in-
flammation (day 0), neutropenia (
 
, 
 
10
 
9
 
 white blood cells/liter) was
induced in mice by repeated subcutaneous injections of cyclophos-
phamide: 150 mg/kg body wt in 200 
 
m
 
l saline on day 
 
2
 
4 and 100 mg/
kg on day 
 
2
 
1. 24 h after the induction of inflammation, when swelling
of the muscle was apparent, mice were injected with 
 
125
 
I-IL-1
 
a
 
, 
 
125
 
I-
IL-1
 
b
 
, free 
 
125
 
I, or with the nonspecific control agent 
 
125
 
I-myoglobin
(microscopic autoradiography) in the tail vein.
 
Microscopic autoradiography.
 
At 2, 6, and 24 h after intravenous
injection of 0.2 ml 2 
 
m
 
g 24 MBq 
 
125
 
I-IL-1
 
a
 
 or 2 
 
m
 
g 24 MBq 
 
125
 
I-myo-
globin (24 h after injection only), groups of three mice were killed
under ether anesthesia by cervical dislocation. 
 
S. aureus
 
–induced
inflammations and contralateral noninflamed calf muscles were
dissected. After removal, excised tissues were immediately fixed in
4% buffered formalin and embedded in paraffin. Four sections of 4 
 
m
 
m
were cut of each excised tissue and mounted on glass slides by con-
ventional procedures. The sections were deparaffinized with xylene
and hydrated by passage through serial dilutions of ethanol. Subse-
quently, slides were dipped in hypercoat LM1 photographic emulsion
(Amersham) in the dark room. The slides were exposed in light-tight
boxes for 3–4 wk at 4
 
8
 
C. After exposure, the emulsions were devel-
oped with Kodak D-19 developer (4 min), washed in water (20 s), and
fixed in 24% thiosulfate (wt/vol, 4 min). The slides were slightly post-
stained with hematoxylin. Parallel series of slides stained with hema-
toxylin and eosin without photographic emulsion were included for
better appreciation of morphology.
The autoradiographs were quantitated by automated image anal-
 
ysis (13). 10 high power fields per inflammation section, i.e., 5 fields in
the area of the cellular infiltration and 5 fields in the area of the unaf-
fected muscle, were selected. Furthermore, five fields per contralat-
eral muscle were selected. The number of grains per field was deter-
mined. The mean number of grains per field was calculated for the
different areas in the tissue.
 
Ex vivo tissue biodistribution.
 
Mice were killed under ether anes-
thesia by cervical dislocation at 5 min, 1, 2, 6, 12, 24, and 48 h after in-
jection of 
 
125
 
I-IL-1
 
a
 
, 
 
125
 
I-IL-1
 
b
 
, or free 
 
125
 
I. Blood samples, inflamed
left calf muscle, right calf muscle, thymus, lungs, spleen, liver, and
kidneys were collected. The dissected tissues were weighed and
counted in the gamma counter. To correct for radioactive decay, in-
jection standards were counted simultaneously. The measured radio-
activity in tissues and samples was expressed as percentage of in-
jected radioactivity dose per gram of tissue (% ID/g).
 
Statistical analysis.
 
All values are expressed as mean
 
6
 
SEM. Sta-
tistical analysis was performed using the one-way ANOVA.
 
Results
 
The uptake of 
 
125
 
I-IL-1
 
a
 
 in inflammation in the course of time.
 
The blood clearance and uptake in inflammation of 
 
125
 
I-IL-1
 
a
 
and free 
 
125
 
I was determined in mice with 
 
S. aureus
 
–induced in-
flammation at various time points (
 
n
 
 5 
 
5 for each preparation
per time point) after intravenous injection of 0.4 MBq 120 ng
of 
 
125
 
I-IL-1
 
a
 
 or 0.4 MBq of free 
 
125
 
I. Despite rapid clearance
from the blood, 
 
125
 
I-IL-1
 
a
 
 accumulated in the inflammation,
reaching maximum values of uptake within 2 h after injection
(Fig. 1 
 
A
 
). 2 h after injection, the uptake of 
 
125
 
I-IL-1
 
a
 
 in in-
flammation decreased. A significant level of 
 
125
 
I-IL-1
 
a
 
 was re-
tained in the inflammatory tissue up to 48 h after injection
(0.8% ID/g). In contrast, 
 
125
 
I-IL-1
 
a
 
 levels in the blood continu-
ously decreased to a level 
 
, 
 
0.05% ID/g at 48 h after injection.
12 h after injection, the uptake of 
 
125
 
I-IL-1
 
a
 
 in inflammation
was significantly higher than the blood levels (
 
P
 
 , 
 
0.005). The
retention of activity in inflammation with time was due to up-
take of 
 
125
 
I-IL-1
 
a
 
 and not of free 
 
125I:free 125I rapidly cleared
from the inflammation in a similar fashion as from the blood
(Fig. 1 B). To be able to study the specific receptor-binding
mechanism of 125I-IL-1 in inflammation, the following studies
focused on the time span of 12–48 h after injection because of
high background activity levels at early time points.
Figure 1. The blood clear-
ance (open circles) and up-
take in S. aureus–induced 
inflammation (closed cir-
cles) of 125I-IL-1a (A) and 
free 125I (B) at various 
time points after injection 
(p.i.). The results are ex-
pressed as percentages
of injected radioactivity 
dose per gram of tissue 
(% ID/g). The error bars 
indicate SEM. The blood 
levels of both 125I-IL-1a 
and free 125I determined 
at 5 min after injection, 
6.660.2 and 8.860.3% 
ID/g, respectively, were 
left out of the figure for 
clarity.
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Comparison of uptake of 125I-IL-1a and 125I-IL-1b in in-
flammation. The biodistribution of both 125I-IL-1a and 125I-IL-1b
was determined in mice with S. aureus–induced inflammations
at various time points (n 5 5 for each radiolabeled preparation
per time point) after intravenous injection of 0.4 MBq 120 ng
of the radiolabeled preparation. The uptake of 125I-IL-1a in in-
flammation was higher than of 125I-IL-1b (Fig. 2). At 48 h after
injection, 0.7660.11% ID/g of 125I-IL-1a was still found in the
inflammation, while levels of 125I-IL-1b decreased to 0.156
0.01% ID/g at 48 h after injection. From 12 h after injection
onwards the uptake of 125I-IL-1a at the site of inflammation
was significantly higher than of 125I-IL-1b (P , 0.05). Due to
the significantly higher uptake of 125I-IL-1a in inflammation as
compared with 125I-IL-1b, further studies exploring the recep-
tor-binding mechanism at the inflammatory site were per-
formed with IL-1a.
Microscopic autoradiography. Microscopic autoradiogra-
phy was applied to study whether systemically administered
radiolabeled IL-1a localizes at the site of infiltrated leukocytes
in induced inflammation in mice. As early as 2 h after injec-
tion, uptake of 125I-IL-1a in the inflammation was observed.
At this time point, most of 125I-IL-1a, found in areas of cellular
infiltration, was localized around the blood vessels. The radio-
label was also found in the unaffected muscular tissue. With
time, 125I-IL-1a was retained within the cellular infiltration,
while the uptake in the unaffected muscle tissue decreased.
After 24 h, nearly all 125I-IL-1a was clearly associated with the
site of inflammatory cells, as demonstrated in Fig. 3, A and B.
In contrast, no specific retention of 125I-IL-1a was found in the
contralateral muscle (Fig. 3 C). The size-matched control pro-
tein 125I-myoglobin did not localize at the site of the inflamma-
tory cells (Fig. 3 D).
The above observations were analyzed quantitatively. The
results are shown in Fig. 4. As early as 2 h after injection, most
125I-IL-1a was found in the area of the cellular infiltration at
2 h after injection. The number of grains in the contralateral
muscle and in areas of unaffected muscular tissue in the in-
flammation decreased during the time course of the experi-
ment. Thus, with time, 125I-IL-1a migrated from the unaffected
muscle tissue to the inflammatory cells within the inflamma-
tion. After 24 h, nearly all grains in the infection were found in
the area of cellular infiltration. At all time points, the number
of grains in the cellular infiltration was significantly higher
than the number of grains in the adjacent unaffected muscle
and the contralateral muscle (P , 0.0001). Furthermore, the
uptake of 125I-IL-1a in the area of the cellular infiltration was
significantly higher than of 125I-myoglobin at 24 h after injec-
tion (P , 0.0001).
Comparison of biodistribution of 125I-IL-1a in immunocom-
petent and neutropenic mice. To study whether the presence
of cellular infiltration is crucial to localization of radiolabeled
IL-1a in inflammation, effects of neutropenia were investi-
gated and compared with observations in immunocompetent
mice. Zymosan, instead of S. aureus, was used for induction of
inflammation in these studies to prevent mortality due to sep-
sis in neutropenic mice. Histology demonstrated that the mas-
sive infiltration of leukocytes, predominantly PMNs, as ob-
served in immunocompetent mice was absent in neutropenic
mice (data not shown). The biodistribution of 125I-IL-1a in im-
munocompetent (n 5 25) and neutropenic mice (n 5 25), de-
termined at various times after intravenous injection of 0.4
MBq 120 ng of the radiolabeled preparation, was similar (Ta-
ble I). 125I-IL-1a rapidly cleared from most organs. However,
one major difference was observed: 125I-IL-1a was retained at
the site of inflammation in immunocompetent mice, while vir-
tually no retention of 125I-IL-1a in the inflammation was found
in neutropenic mice (Fig. 5). At all time points, the uptake of
125I-IL-1a at the site of inflammation was significantly higher
in immunocompetent mice than in neutropenic mice (P ,
0.001). Maximum differences were obtained at 48 h after injec-
tion; the uptake of 125I-IL-1a in inflammation was . 12 times
higher in immunocompetent mice compared with neutropenic
mice, 0.6560.06 and 0.0560.004% ID/g, respectively.
Effect of in vivo blockade of IL-1Rs on localization of
125I-IL-1a in inflammation. To elucidate whether type I and/
or type II IL-1R is/are involved in entrapment of radioiodi-
nated IL-1a in inflammation, groups of five mice with S. au-
reus–induced inflammations were injected intravenously with
200 mg anti–type I IL-1R antibody 35F5, 200 mg anti–type II
IL-1R antibody 4E2, or a mixture of both antibodies (200 mg
of each antibody) in 100 ml sterile saline at 6 h and 5 min be-
fore intravenous injection of 0.4 MBq 120 ng 125I-IL-1a. Con-
trol mice (n 5 5) were injected intravenously with 100 ml ster-
ile saline before injection of 125I-IL-1a. As depicted in Fig. 6,
mice with type I IL-1R blockade displayed significantly higher
uptake of 125I-IL-1a in the inflammation than the control
group, i.e., 2.2660.12 vs. 0.6560.05% ID/g at 48 h after injec-
tion (P , 0.0001). In contrast, the uptake of 125I-IL-1a at the
site of inflammation in mice with blockade of type II IL-1Rs
(0.1360.009) was significantly lower than the value obtained
in control mice (P , 0.0001). A similar low uptake of 0.146
0.009% ID/g in inflammation was found in mice with both type
I and type II IL-1R blockade. The 125I-IL-1a levels in the blood
and all other organs were similar for all studied groups (data
not shown).
Discussion
This study confirms the hypothesis that systemically adminis-
tered radiolabeled IL-1a localizes in acute inflammatory foci
by specific receptor binding. As demonstrated by microscopic
autoradiography, IL-1a localized within the inflammation at
the site of the infiltrated leukocytes, which were predomi-
Figure 2. The uptake of 125I-IL-1a and 125I-IL-1b in S. aureus–
induced inflammation in mice at 24 (striped bars) and 48 h (open 
bars) after injection. The results are expressed as percentages of in-
jected radioactivity dose per gram of tissue (% ID/g). The error bars 
indicate SEM.
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nantly PMNs. The studies with neutropenic mice corroborated
these findings, since low uptake of IL-1a in inflammation
was found in the absence of cellular infiltration. Moreover, the
IL-1 receptor blockade studies showed that the retention of
IL-1a in inflammatory tissue was inhibited by blockade of
type II IL-1Rs.
The binding of human recombinant IL-1 to murine leuko-
cytes, predominantly PMNs, has also been described by Parker
et al. (4). In their studies in mice, PMNs were removed from
peritoneal exudate to test the binding of radiolabeled IL-1 to
these cells ex vivo. Our results show binding of systemically
administered radiolabeled IL-1 to murine infiltrated leuko-
cytes in acute inflammation in vivo. The receptor binding ca-
pacity of IL-1 after radiolabeling was tested in vitro on murine
thymoma cells. The affinity was as high as reported in earlier
studies (2, 5). It was not possible to isolate leukocytes from the
inflammatory tissue in mice to test the binding to these cells ex
vivo. Therefore, microscopic autoradiography was used to vi-
sualize the localization of 125I-IL-1a in the cellular infiltration
of inflammatory tissue. This method has also been used by oth-
ers to identify IL-1 receptors in various noninflamed murine
tissues (14, 15). To exclude nonspecific accumulation in in-
flammatory foci by locally increased vascular permeability
(16–18), inflammatory tissue of mice injected with the control
agent 125I-myoglobin was also subjected to microscopic autora-
diography, showing no localization in the cellular infiltration.
This indicates that IL-1a is retained in inflammatory foci by
specific binding to its receptors.
For most of our studies, S. aureus–induced focal infections
were used. These infections are characterized by massive in-
flammatory cell infiltration. Mice with a focal S. aureus infec-
tion do not show general signs of illness. However, neutro-
penic mice with such infections become severely ill and die
within 1–3 d, most likely due to sepsis. To allow comparison of
uptake of radiolabeled IL-1a in inflammation in neutropenic
and immunocompetent mice, the sterile zymosan model was
chosen, which in immunocompetent mice induces a massive
focal infiltration of PMNs and monocytes (19, 20). Neutro-
penic mice with zymosan-induced inflammations did not show
any signs of illness. No cellular infiltration was found in the in-
duced inflammations of these mice. Despite similar biodistri-
bution in both groups of mice, the uptake of 125I-IL-1a at the
site of inflammation was significantly higher in immunocompe-
tent mice, again stressing the fact that radiolabeled IL-1a accu-
Figure 3. Microscopic autoradiography of inflammatory tissue of a mouse 24 h after injection with 125I-IL-1a, without photographic emulsion 
(hematoxylin and eosin, 3400) (A) and approximately the same area with photographic emulsion (hematoxylin, 3400) (B). (C) The correspond-
ing contralateral muscle with photographic emulsion (hematoxylin, 3400). (D) Inflammatory tissue with photographic emulsion of a mouse 24 h 
after injection of the control agent 125I-myoglobin (hematoxylin, 3400).
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mulates in inflammatory tissue by means of binding to its re-
ceptors on infiltrated leukocytes.
The IL-1R blockade studies showed that the binding of ra-
diolabeled IL-1a to infiltrated leukocytes was mainly due to
binding to type II IL-1Rs. The inflammation uptake of IL-1a
was significantly lower in case of blockade of type II IL-1Rs.
Surprisingly, increased uptake of radiolabeled IL-1a in the in-
flammation was found when type I IL-1Rs were blocked.
Blockade of type I IL-1Rs, expressed on a wide range of cells
in the body, may have increased levels of free IL-1a, available
for binding to type II IL-1Rs, expressed on infiltrated neutro-
phils and monocytes in the inflammation. When both type I and
type II IL-1Rs were blocked, inflammation uptake of IL-1a
was as low as that found with type II IL-1R blockade only.
This indicates that the increased uptake of IL-1a in inflamma-
tory tissue (obtained by blockade of type I IL-1Rs) could be
completely inhibited by blockade of type II IL-1Rs. Therefore,
aspecific increased uptake of IL-1a in inflammation in case of
type I IL-1R blockade could be ruled out. Binding to soluble
type II IL-1Rs, increased during various inflammatory condi-
tions (21–23), could also be excluded since the used anti–type
II antibody 4E2 also binds and neutralizes these receptors.
Although blockade of binding of radiolabeled IL-1a to
type II IL-1Rs with the antibody 4E2 has been demonstrated
in vitro on cell lines (24), in vivo, blockade of type II IL-1Rs
did not affect particular studied biologic effects of IL-1a (7,
10). Since it is now generally accepted that the type II IL-1R
acts as a decoy receptor for IL-1 (25–28), no direct effects of
type II IL-1R blockade on IL-1 induced biologic activity are to
be expected. Indirectly, type II IL-1R blockade may enhance
Figure 4. The quantitative analysis of microscopic autoradiography 
of inflammation (infiltration, open bars, and adjacent muscle, heavily 
striped bars) and contralateral muscle (striped bars) sections of mice 
injected with either 125I-IL-1a or 125I-myoglobin (at 24 h after injec-
tion only), expressed as mean number of grains per field 6SEM.
Figure 5. The uptake of 125I-IL-1a in zymosan-induced inflammation 
in neutropenic and immunocompetent mice at 24 (striped bars) and 
48 h (open bars) after injection. The results are expressed as percent-
ages of injected radioactivity dose per gram of tissue (% ID/g). The 
error bars indicate SEM.
Table I. Biodistribution of 125I-IL-1a in Neutropenic and Immunocompetent Mice with Zymosan-induced Inflammation
Organ Neutropenia 2 h p.i.* 6 h p.i. 12 h p.i. 24 h p.i. 48 h p.i.
Blood 1 4.7960.19 2.1260.12 0.5260.12 0.1860.01 0.0460.004
2 4.1060.33 1.4960.13 0.2860.009 0.1360.01 0.0860.009
Inflammation 1 1.6760.14 0.9660.06 0.3660.04 0.2460.06 0.0560.004
2 2.9060.17 2.2060.05 1.3360.14 0.9660.02 0.6560.06
Muscle 1 0.7760.04 0.3660.04 0.0860.02 0.0460.006 0.0160.002
2 1.1860.40 0.2560.02 0.0860.004 0.0460.002 0.0260.004
Thymus 1 2.3560.28 1.4660.23 0.3560.10 0.1460.01 0.0760.02
2 1.3860.22 0.8560.21 0.2460.03 0.1260.02 0.0660.004
Lung 1 3.8960.23 1.8660.06 0.4960.14 0.1860.01 0.0660.008
2 5.3260.70 1.4560.02 0.3160.02 0.1460.006 0.1160.02
Spleen 1 4.7060.25 1.4460.10 0.3860.10 0.1560.006 0.0660.004
2 4.6860.64 1.3660.11 0.3560.05 0.1460.03 0.0760.009
Liver 1 4.6760.25 1.2660.06 0.3860.06 0.1960.02 0.1060.004
2 3.2660.28 0.9160.10 0.3260.01 0.1960.01 0.1660.009
Kidney 1 5.2760.26 1.7960.09 0.5860.10 0.2760.01 0.1660.008
2 4.6760.45 1.2560.14 0.4160.02 0.2660.006 0.1860.01
*All values are expressed as percentage of injected dose per gram of tissue. p.i., postinjection.
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IL-1–induced biologic activity, as shown by others in vitro (25,
26), but this may be more difficult to demonstrate in vivo. The
effects of type II IL-1R blockade on IL-1–induced biologic ac-
tivity were not evaluated, but the inhibition of receptor bind-
ing of radiolabeled IL-1a at the site of inflammation by type II
IL-1R blockade could be shown in vivo.
The uptake of IL-1b in inflammation was lower than the
uptake of IL-1a. Apparently, lower amounts of IL-1b bound
to IL-1Rs in the inflammatory tissue. Since systemically ad-
ministered IL-1 appears to mainly bind to type II IL-1Rs, these
findings are in line with data obtained by Parker et al. (4).
They also tested the binding of human recombinant IL-1a and
IL-1b for the type II IL-1R on murine PMNs and found a two-
to threefold lower affinity for IL-1b as compared with IL-1a.
Opposite results have been reported for the binding of human
recombinant IL-1a and IL-1b to the human type II IL-1R (29,
30), indicating that species differences play a role in receptor-
binding characteristics of IL-1a and IL-1b.
Although the total amount of radiolabeled IL-1a in the in-
flammation decreased with time, retention was still found at 48 h
after injection. Most likely, as demonstrated by the micro-
scopic autoradiography results, IL-1a accumulates in inflam-
matory tissue shortly after injection and migrates toward the
binding sites on infiltrated leukocytes during the next 24 –48 h.
Some IL-1a molecules will bind easily accessible receptors
early after injection and others reach binding sites several
hours thereafter. After 24 h, radiolabeled IL-1a, retained in
the inflammation, could almost only be found in areas of cellu-
lar infiltration. In the meantime, most of the unbound and/or
degraded IL-1a is cleared from the tissue, resulting in a de-
creasing total amount of radiolabeled IL-1a in the inflamma-
tion. Despite the latter, the uptake in areas of cellular infiltra-
tion even increased with time, which could be explained by the
fact that these areas form the minority of the total inflamma-
tion. Since IL-1a seemed to bind mainly to type II IL-1Rs in
the models of inflammation studied, these observations may
be conflicting with data suggesting poor internalization of re-
ceptor-bound IL-1 (31) and a fast turnover of the receptor (2 h)
(32). However, these characteristics were observed in vitro us-
ing the Raji human B lymphoma cell line. In vivo, IL-1 binding
to type II receptors on activated leukocytes in inflammatory
tissue may be different.
This study supports first indications that systemically ad-
ministered radiolabeled IL-1a localizes in inflammation by
specific receptor binding. The type II IL-1R appeared to be
the predominant binding site in acute inflammation models.
Actual binding of IL-1a to type II IL-1R in inflammatory tis-
sue could be demonstrated. Future studies will focus on the in
vivo behavior of IL-1a and the correlation with IL-1R expres-
sion in various other inflammation models.
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